Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis

Journal of the American Academy of Dermatology

Volumn 63, Issue 5, 2010, Pages 775-781

  Levine, Danielle ^a   Even Chen, Zeev ^b   Lipets, Irina ^c   Pritulo, Olga A ^d   Svyatenko, Tetyana V ^e   Andrashko, Yuri ^f   Lebwohl, Mark ^g   Gottlieb, Alice ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dermipsor   (Israel)

^c Global Clinical Operations PharmaEdge Research   (United States)

^d V I VERNADSKY CRIMEAN FEDERAL UNIVERSITY   (Russian Federation)

^e Dnipropetrovsk State Medical Academy   (Ukraine)

^f INSTITUTE OF HYDROBIOLOGY   (Ukraine)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

calcipotriene; nicotinamide; psoriasis; randomized control trial; topical psoriasis treatment

Indexed keywords

ANTIPSORIASIS AGENT; CALCIPOTRIOL; DPS 101; NICOTINAMIDE; PLACEBO; UNCLASSIFIED DRUG;

APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSIVE CRISIS; MORNING DOSAGE; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NIACINAMIDE; PILOT PROJECTS; PLACEBOS; PSORIASIS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 77957996820     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.10.016     Document Type: Article

References (8)

1. L. Barnes, P. Altmeyer, L. Fôrstrôm, and M.H. Stenström Long-term treatment of psoriasis with calcipotriol scalp solution and cream Eur J Dermatol 10 2000 199 204
2. M.R. Namazi Nicotinamide: a potential addition to the anti-psoriatic weaponry FASEB J 17 2003 1377 1379
3. J.S. Ungerstedt, M. Blömback, and T. Söderström Nicotinamide is a potent inhibitor of proinflammatory cytokines Clin Exp Immunol 131 2003 48 52
4. P.F. Lizzul, A. Aphale, R. Malaviya, Y. Sun, S. Masud, and V. Dombrovskiy Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept J Invest Dermatol 124 2005 1275 1283
5. A. Wozniacka, P. Szajerski, J. Adamus, J. Gebicki, and A. Sysa-Jedrzejowska In search for new antipsoriatic agents: NAD topical composition Skin Pharmacol Physiol 20 2007 37 42
6. R. Kaufmann, A.J. Bibby, R. Bissonnette, F. Cambazard, A.C. Chu, and J. Decroix A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris Dermatology 205 2002 389
7. J. Koo, R.R. Blum, and M. Lebwohl A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes J Am Acad Dermatol 55 2006 637
8. K. Kragballe, J. Austad, L. Barnes, A. Bibby, M. de la Brassinne, and F. Cambazard Efficacy results of a 52-week, randomized, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris Dermatology 213 2006 319 326 (Pubitemid 44837020)